Search results for: weight

Is Hydroxychloroquine Safe During Pregnancy?

Arthritis & Rheumatology | March 31, 2022

Chambers et al. found no evidence of an increased risk of major structural birth defects nor any increase in a wide range of other pregnancy outcomes attributable to prenatal exposure to hydroxychloroquine.

Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

Jason Liebowitz, MD, FACR | March 23, 2022

At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting at Johns Hopkins School of Medicine, Baltimore, Atul Deodhar, MD, discussed ankylosing spondylitis and non-radiographic axial spondyloarthritis & clarified common misconceptions about these conditions.

Case Report: Perplexing Pulmonary Nodules

Monsoon Rashid, DO, & Deana Lazaro, MD | March 14, 2022

Pulmonary nodules are common; most are benign, but the differential diagnosis is broad and includes life-threatening possibilities.1 Our patient is a former smoker who has a history of a complex autoimmune disease and multiple pulmonary nodules. This case was challenging, but clinical, radiographic and histologic clues helped lead to the correct diagnosis. Case Presentation The…

Medium-sized blood vessels are seen in the dermis and at the dermal-subcutaneous junction. The black arrow identifies a venule, and the blue arrow points to a fibrin deposition in the vessel wall. Extravasated neutrophils and erythrocytes are seen in the interstitium.

Case Report: A Polyarteritis Nodosa Conundrum

Hannah Krebsbach, MD, Ileannette Robledo Vega, MD, Nirupa Patel, MD, & Nkechinyere Emejuaiwe, MD, MPH | March 14, 2022

Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries. The clinical subsets of PAN are idiopathic, generalized, secondary hepatitis B virus (HBV) associated and cutaneous PAN. These clinical subsets are important because of their therapeutic implications. Virtually any organ system can be affected in generalized PAN, but this vasculitis tends…

Back to Basics: RheumMadness 2022 Increasing ANA Positivity Scouting Report

University of Chicago School of Medicine: Lauren He, MD; Ana B. Arevalo, MD; & Kichul Ko, MD | March 3, 2022

Research has revealed how the prevalence of anti-nuclear antibody (ANA) positivity has changed over the past 25 years, raising questions about the role of ANA in autoimmunity and disease.

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Mary Choy, PharmD, BCGP, FASHP | February 10, 2022

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors

Arthritis & Rheumatology | February 2, 2022

In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.

Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica

Michele B. Kaufman, PharmD, BCGP | January 1, 2022

In a study, patients with new-onset polymyalgia rheumatica (PMR) who were treated with subcutaneous tocilizumab were more likely to achieve sustained, glucocorticoid-free remission than patients who received placebo.

The Transformative Power of Tragedy

Philip Seo, MD, MHS | December 16, 2021

On Sept. 11, 2001, I was at work. I had accepted a position as an assistant chief of service (ACS) for the Department of Medicine, which is Hopkins-speak for a hybrid position that involves all the administrative duties of a chief resident, plus the responsibility of an attending. For a year, I admitted patients to…

Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

Michele B. Kaufman, PharmD, BCGP | December 9, 2021

Researcher identified multiple factors for flare, including non-use of methotrexate, in patients with rheumatoid arthritis who had switched from intravenous (IV) tocilizumab to subcutaneous tocilizumab.